Data / Form D filings / VerImmune, Inc.
VerImmune, Inc.: Form D filings
VerImmune, Inc., a biotechnology company in Bethesda, MD, filed 2 Form D notices with the SEC between 2022 and 2024. The latest, on September 25, 2024, reports $4.5 million sold of a $8 million offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 7200 WISCONSIN AVE, SUITE 500, Bethesda, MD, 20814
- Phone
- (443) 449-8836
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1903915
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 25, 2024 | New notice | $8,000,000 | $4,495,354 | $3,504,646 | 6 | Aug 27, 2024 | sec.gov |
| Mar 31, 2022 | New notice | $2,500,000 | $1,379,975 | $1,120,025 | 9 | Mar 18, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| CYNTHIA KOH POH | Director | |
| KEVIN KOH RONGSHENG | Director | |
| HAOLIN SUNG | Director | |
| CHE KOH HSU | Director | |
| MARTA KOH NEW | Director | |
| JOSHUA WANG | Executive Officer, Director, Promoter | |
| ROGER KOH POMERANTZ | Director |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Sep 23, 2024 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what VerImmune, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.